Latest Industry Insights

As the global population ages, the need for innovative solutions to extend health span and combat age-related diseases has never been more urgent. LinkGevity, a pioneering AI-enabled drug discovery company, is at the forefront of this challenge.

Mushroom mycelium can be turned into high-quality insulation and other building materials. To learn more, Technology Networks spoke with the founder of MycoTile, a Kenyan company that specializes in mycelium-based construction materials.

In this interview, Susan Bird, senior manager at Thermo Fisher Scientific, discusses the analytical challenges of identifying low-level exposures and how cutting-edge mass spectrometry platforms are advancing exposomics research.

Dr. Madhuri Hegde discusses Revvity's role in the Generation Study, an ambitious initiative that will sequence the genomes of 100,000 newborns.

Discover how induced pluripotent stem cell technology is solving scale and consistency issues in mesenchymal stem/stromal cell therapy manufacturing and learn about Cynata’s ongoing clinical trials.

James Connelly discusses the importance of third-party verification and how recent funding will help accelerate the development of Impact Laboratories' digital sustainability tools.

Technology Networks spoke with Dr. Irina Babina, chief executive officer of Concr, to explore the origins of the company, the science behind its platform and the tangible impact it hopes to deliver for patients and healthcare systems alike.

Technology Networks spoke with Dr. Jenny Bailey Cooper, co-founder and CEO of Ferryx, to learn the science behind its lead product, Ferrocalm^TM, and how its innovative strategy could reshape the future of gut health.

Portal Bio’s microfluidic technology enhances drug discovery and cell engineering by enabling efficient, scalable molecular delivery for sensitive cell types.

At the BioTrinity 2025 conference, Technology Networks spoke with Dr. Pedro Correa de Sampaio, co-founder and CEO of Neobe, who are utilizing synthetic biology to engineer bacteria capable of breaking down the barriers within tumors.